Treatment of early hepatocellular carcinoma: Towards personalized therapy

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S242-S248

  Tremosini, Silvia ^a   Reig, María ^a   de Lope, Carlos Rodríguez ^a   Forner, Alejandro ^a   Bruix, Jordi ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Ablation; Hepatocellular carcinoma; Personalized therapy; Surgical resection; Transplantation

Indexed keywords

ARTICLE; CANCER SURVIVOR; CLINICAL EFFECTIVENESS; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT DECISION MAKING; PATIENT SAFETY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR ABLATION; TUMOR VOLUME; ABLATION THERAPY; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; LIVER CIRRHOSIS; LIVER NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE;

ABLATION TECHNIQUES; CARCINOMA, HEPATOCELLULAR; HUMANS; INDIVIDUALIZED MEDICINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PATIENT SELECTION;

EID: 77953706324     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60512-9     Document Type: Article

References (47)

1. Bruix J, Llovet JM Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.
2. D'Amico G, Garcia-Tsao G, Pagliaro L Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006, 44:217-231.
3. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nati Cancer Inst 2008, 100:698-711.
4. Forner A, Reig M, Rodrigruez de Lope C, et al. Current Strategy for Staging and Treatment: the BCLC Update and Future Prospects. Semin Liver Dis 2010, 30:61-74.
5. Hepatology 1998, 28:751-755. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.
6. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
7. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
10. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
11. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009, 49:658-664.
12. Kojiro M, Roskams T Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005, 25:133-142.
13. Hepatocellular carcinoma 1987, Springer-Verlag, Tokyo. T. Nakashima, M. Kojiro (Eds.).
14. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996, 111:1018-1022.
15. Llovet JM, Fuster J, Bruix J Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
16. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection?. Ann Surg 2009, 250:922-928.
17. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008, 134:1908-1916.
18. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
19. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000, 119:431-440.
20. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003, 237:208-217.
21. Tanaka H, Hirohashi K, Kubo S, et al. Preoperative portal vein em-bolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function. Br J Surg 2000, 87:879-882.
22. Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996, 87:206-211.
23. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561-1567.
24. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356:802-807.
25. Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002, 3:593-603.
26. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
27. Marsh JW, Dvorchik I Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl 2003, 9:693-696.
28. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
29. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
30. Rimola A, Llovet JM, Navasa M, et al. Applicability of adult-to-adult living donor liver transplantation. J Hepatol 2005, 43:104-109.
31. Kawasaki S Living-donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2002, 49:53-55.
32. Sugawara Y, Tamura S, Makuuchi M Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007, 25:310-312.
33. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008, 14:935-945.
34. Todo S, Furukawa H Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004, 240:451-459. discussion 459-61.
35. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008, 8:679-687.
36. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
37. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746-1756.
38. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004, 10:1294-1300.
39. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
40. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-240.
41. Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003, 226:441-451.
42. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. Hepatology 2008, 47:82-89.
43. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgi-cal treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000, 32:1224-1229.
44. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40:1352-1360.
45. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995, 197:101-108.
46. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004.
47. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.